Merrimack licensed Baxter its Phase III pancreatic cancer candidate MM398 for $100 million up front and $620 million in pre-commercial milestones; Merck KGAA added life sciences products in its $16.7 billion acquisition of Sigma-Aldrich. Biopharma and device financing were both up from the previous month.
Exhibit 1
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
An interactive look at pharma, medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
